Robert J. Jr. Marshall Sells 10,000 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Lantheus Stock Performance

Shares of NASDAQ:LNTH traded down $1.14 during mid-day trading on Friday, hitting $97.71. The stock had a trading volume of 1,069,481 shares, compared to its average volume of 936,960. The company's 50 day moving average is $92.67 and its 200-day moving average is $96.58. Lantheus Holdings, Inc. has a 12-month low of $57.92 and a 12-month high of $126.89. The company has a market cap of $6.69 billion, a PE ratio of 16.26 and a beta of 0.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. On average, equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Remove Ads

Hedge Funds Weigh In On Lantheus

Institutional investors and hedge funds have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus during the third quarter worth approximately $25,000. Kestra Investment Management LLC purchased a new stake in Lantheus in the 4th quarter worth approximately $27,000. Summit Securities Group LLC acquired a new stake in shares of Lantheus during the 4th quarter valued at $37,000. UMB Bank n.a. grew its holdings in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after acquiring an additional 134 shares in the last quarter. Finally, World Investment Advisors LLC acquired a new position in shares of Lantheus in the third quarter worth $60,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on LNTH. JMP Securities restated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial raised their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price target on the stock. Finally, B. Riley cut their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Lantheus currently has an average rating of "Moderate Buy" and an average target price of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.